- Home
- SXTC vs SLXN Comparison
SXTC vs SLXN Comparison
Compare SXTC & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- SLXN
- Stock Information
- Founded
- SXTC 2005
- SLXN 2008
- Country
- SXTC China
- SLXN Israel
- Employees
- SXTC N/A
- SLXN N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- SXTC Health Care
- SLXN
- Exchange
- SXTC Nasdaq
- SLXN NYSE
- Market Cap
- SXTC 2.5M
- SLXN 3.0M
- IPO Year
- SXTC 2019
- SLXN N/A
- Fundamental
- Price
- SXTC $0.39
- SLXN $0.21
- Analyst Decision
- SXTC
- SLXN Strong Buy
- Analyst Count
- SXTC 0
- SLXN 1
- Target Price
- SXTC N/A
- SLXN $1.00
- AVG Volume (30 Days)
- SXTC 206.0K
- SLXN 1.5M
- Earning Date
- SXTC 01-01-0001
- SLXN 11-14-2024
- Dividend Yield
- SXTC N/A
- SLXN N/A
- EPS Growth
- SXTC N/A
- SLXN N/A
- EPS
- SXTC N/A
- SLXN N/A
- Revenue
- SXTC $1,928,497.00
- SLXN N/A
- Revenue This Year
- SXTC N/A
- SLXN N/A
- Revenue Next Year
- SXTC N/A
- SLXN N/A
- P/E Ratio
- SXTC N/A
- SLXN N/A
- Revenue Growth
- SXTC N/A
- SLXN N/A
- 52 Week Low
- SXTC $0.37
- SLXN $0.21
- 52 Week High
- SXTC $6.39
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- SXTC 29.34
- SLXN N/A
- Support Level
- SXTC $0.45
- SLXN N/A
- Resistance Level
- SXTC $0.51
- SLXN N/A
- Average True Range (ATR)
- SXTC 0.06
- SLXN 0.00
- MACD
- SXTC -0.01
- SLXN 0.00
- Stochastic Oscillator
- SXTC 5.97
- SLXN 0.00
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.